scholarly journals Period Analysis of Intraracial Differences in Incidence and Survival Rates in Epithelial Ovarian Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Lili Han ◽  
Sulaiya Husaiyin ◽  
Jing Liu ◽  
Miherinisha Maimaiti ◽  
Mayinuer Niyazi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Survival Rate ◽  
Epithelial Ovarian Cancer ◽  
Median Survival ◽  
Survival Rates ◽  
Relative Survival ◽  
Population Based ◽  
Relative Survival Rate ◽  
Kaplan Meier ◽  
The Difference

Background. To explain the difference in the incidence and relative survival in a population-based cohort of women with epithelial ovarian cancer (EOC) postdiagnosis in the last forty years. EOC is the most common type of all ovarian cancers, but there is inadequate information about the variations related to long-term EOC survival. Methods. We acquired the incidence and relative survival rate data from the Surveillance, Epidemiology, and End Results (SEER) registries to analyze the epidemiological variations from 1974 to 2013 in EOC-affected individuals. The survival disparities in EOC-specific individuals due to age, race, and socioeconomic status (SES) were performed by Kaplan-Meier analysis. The Results. The overall incidence of EOC progressively declined to 9.0 per 100,000 from 11.4 in the last forty years. The median survival rate improved to 48 months in the first decade from a previous of 27 months in the fourth decade. The 5-year relative survival rate (RSR) increased to 44.3% that was previously 32.3% at the same time. However, between whites and blacks, an increase from 11 to 18 months was observed in the median survival differences. Between the low and high poverty groups, it was increased from 7 months to 12 months, respectively. Conclusions. The incidence rate of RSR and EOC-specific individuals in the last forty years was improved. However, the survival rates among different races and SES differed over time.

scholarly journals Widened difference of incidence and survival between different races in epithelial ovarian cancer: a period analysis.

2020 ◽  
Author(s):  
Li Li ◽  
Lili Han ◽  
Sulaiya Husaiyin ◽  
Miherinisha Maimaiti ◽  
Mayinuer Niyazi
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Median Survival ◽  
Survival Data ◽  
Relative Survival ◽  
Population Based ◽  
Limited Information ◽  
Term Survival ◽  
The Past ◽  
Survival Differences

Abstract Introduction To describe the incidence and relative survival in women with epithelial ovarian cancer (EOC) in a population-based cohort in the four decades after diagnosis. EOC is the major pathological type of all ovarian cancers, however, there is limited information on changes of long-term survival in EOC in the four decades. Methods We extracted the incidence and relative survival data from Surveillance, Epidemiology, and End Results (SEER) registries to assess epidemiological changes of patients with EOC from 1974 to 2013. The survival disparities of patients with EOC among four decades, age, race, and socioeconomic status (SES) were performed by Kaplan-Meier curves. Results The overall incidence of EOC gradually declined from 11.4 to 9.0 per 100,000 in the past four decades. The median survival increased from 27 months in the first decades to 48 months in the fourth decade, with 5-year relative survival rate (RSR) improving from 32.3% to 44.3% in the same period. However, the median survival differences increased from 11 months to 18 months between Whites and Blacks and increased from 7 months to 12 months between low-poverty group and high-poverty group respectively over the past four decades. Discussion This study indicated that the incidence and RSR of EOC patients had improved in the past four decades. But the survival gap between different races and SES gradually widened. More importantly, this study will promote the improvement of health care system and clinical management to erase the survival differences in SES groups and races identified in this study, thereby optimize the clinical outcome.

State of the Russian Oncology Service: malignant neoplasms of the tongue C01, 02 (mortality rate in patients, median survival of patients, taking into account the stage of the disease and the histological structure of the tumor). Part II

2021 ◽  
Author(s):  
Vakhtang M. Merabishvili ◽  
Elvira N. Merabishvili ◽  
Alexander M. Shcherbakov ◽  
Alexander B. Vasiliev ◽  
Alexey F. Barsukov ◽  
...  
Keyword(s):  
Survival Rate ◽  
Mortality Rate ◽  
Cancer Patients ◽  
Median Survival ◽  
Tongue Cancer ◽  
Survival Rates ◽  
Relative Survival ◽  
Population Based ◽  
Malignant Neoplasms ◽  
Oncology Service

Malignant neoplasms of the tongue occupy 0.55% in the general structure of the cancer incidence in Russian population. No information on other parameters (the number of deaths, mortality of patients, their distribution by stages of the disease and other analytical indicators) is provided in the official reporting. The opportunity appeared only with the development of Population-based Cancer Registries (PCR) system, but this wealth of material is not used for the official reporting. Tongue cancer is a visual localization with a high mortality rate, which requires special attention. The study was conducted to investigate the state of Russian Oncology Service for tongue cancer patients with the calculations of one-year mortality rate, annual mortality rate, median survival, 1,3,5-year observed and relative survival rates, first time in Russia, at the level of the newly created Population-based Cancer Registry of the Federal District. In Russia, there has been little research on the analysis of the cancer survival rate at the population level. We have been conducting developments for all malignant tumors localizations since 2000 based on the St. Petersburg PCR database. The level of 5-year observed and relative survival rates for tongue cancer patients in Russia (St. Petersburg and the NWFD RF) has been found to be significantly lower than the EU average (Eurocare-4). To carry out this study, 5188 observations from the NWFD RF PCR database were selected. It has been established that during 4 periods of observation, the mortality rate for tongue cancer patients during the first year of observation in the NWFD RF has decreased under the C01 rubric (cancer of the base of the tongue) from 58.5 to 45.8%; and under the C02 rubric (malignant neoplasm of other and unspecified parts of tongue) from 54.5 to 42.7%. The five-year survival rate for tongue cancer patients has increased by 23.3%.

scholarly journals Primary Central Nervous System Lymphoma High Incidence And Poor Survival In Finnish Population-Based Analysis

2021 ◽  
Author(s):  
Inka Puhakka ◽  
Hanne Kuitunen ◽  
Pekka Jäkälä ◽  
Eila Sonkajärvi ◽  
Taina Turpeenniemi-Hujanen ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Survival Rate ◽  
Survival Rates ◽  
Central Nervous System Lymphoma ◽  
Relative Survival ◽  
B Cell Lymphoma ◽  
Population Based ◽  
Incidence Rates ◽  
Relative Survival Rate

Abstract Background: We report here the first population-based incidence rates and prognosis of primary central nervous system lymphoma (PCNSL) in Finland. Methods: Finnish Cancer Registry data by histological diagnosis and tumor location (2007-2017) for cases with diffuse large B-cell lymphoma.Results: During 2007–2017, 392 new cases of PCNSL were reported (195 males, 197 females). The average age-adjusted incidence was 0.68/100.000 person-years. Incidence for males was 0.74/100.000 and for females 0.63/100.000, respectively. The incidence was highest, 2.93/100.000, among people aged 75–79 years. Concerning all cases in 2007-2017 the 2-year age-adjusted relative survival rate was 35% and the corresponding 5-year survival rate was 28%. Among patients under the age of 70, the age-adjusted 5-year relative survival rate increased from 36% in 2007-2012 to 43% for 2013-2017. Among patients aged 70+ the corresponding survival rates were poor, 7% and 9%.Conclusions: PCNSL incidence in Finland is among the highest reported in the world. The annual increase in incidence was 2.4%. The prognosis is still dismal, especially in elderly patients.

scholarly journals The Clinicopathologic Characteristics and 3-Year Survival Rates of Epithelial Ovarian Cancer in Iran During 2011-2017

2018 ◽  
Vol 7 (4) ◽  
pp. 496-500
Author(s):  
Shahrzad Sheikh Hasani ◽  
Mitra Modares Gilani ◽  
Setareh Akhavan ◽  
Azam-Sadat Mousavi ◽  
Elham Saffarieh ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Survival Rate ◽  
Epithelial Ovarian Cancer ◽  
Mucinous Adenocarcinoma ◽  
Survival Rates ◽  
Newly Diagnosed ◽  
Clinicopathologic Characteristics ◽  
Cross Sectional ◽  
Treatment Type

Objectives: The aim of this study was to determine the 3-year overall survival among the epithelial ovarian cancer patients based on the histology, age, and the stage of the disease in Iran during 2011-2017. Materials and Methods: This study was a cross-sectional retrospective study that was conducted on 179 newly diagnosed patients with epithelial ovarian cancer, who had referred to the gynecologic cancers clinic in a referral training hospital in Tehran during 2011-2017. The patients’ data including the demographic characteristics of the patients, the stage of the disease, and the treatment type were analyzed based on the pathologic responses. Results: Among 220 newly diagnosed patients with epithelial ovarian cancer, 179 of them were suitable for the follow-up. There were 93 death and 85 living cases among these patients and the mean age of the patients was 50.5 ± 11.3. In addition, most of the patients were in stage 3 (60.9%) and 6.7% of them were in stage 4. The most common pathology was serous adenocarcinoma (70.9%). In this study, the overall survival rate had no connection with the type of tumor histology but it was related to the stage of the disease (P=0.05). Finally, there was no mortality in stage one and among the mucinous adenocarcinoma cases. Conclusions: The survival in the epithelial ovarian cancer was related to the stage of the disease and among all the pathologies, mucinous adenocarcinoma and clear cell carcinoma had the best survival rate.

scholarly journals CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016

2019 ◽  
Vol 21 (Supplement_5) ◽  
pp. v1-v100 ◽  
Author(s):  
Quinn T Ostrom ◽  
Gino Cioffi ◽  
Haley Gittleman ◽  
Nirav Patil ◽  
Kristin Waite ◽  
...  
Keyword(s):  
United States ◽  
Central Nervous System ◽  
Nervous System ◽  
Survival Rate ◽  
Incidence Rate ◽  
Relative Survival ◽  
The United States ◽  
Population Based ◽  
Cns Tumors ◽  
Relative Survival Rate

AbstractThe Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 23.41 (Malignant AAAIR = 7.08, non-Malignant AAAIR = 16.33). This rate was higher in females compared to males (25.84 versus 20.82), Whites compared to Blacks (23.50 versus 23.34), and non-Hispanics compared to Hispanics (23.84 versus 21.28). The most commonly occurring malignant brain and other CNS tumor was glioblastoma (14.6% of all tumors), and the most common non-malignant tumor was meningioma (37.6% of all tumors). Glioblastoma was more common in males, and meningioma was more common in females. In children and adolescents (age 0–19 years), the incidence rate of all primary brain and other CNS tumors was 6.06. An estimated 86,010 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US in 2019 (25,510 malignant and 60,490 non-malignant). There were 79,718 deaths attributed to malignant brain and other CNS tumors between 2012 and 2016. This represents an average annual mortality rate of 4.42. The five-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 35.8%, and the five-year relative survival rate following diagnosis of a non-malignant brain and other CNS tumors was 91.5%.

Analyzing Survival Trends in Multiple Myeloma Patients in Pre and Post-Bortezomib Era Using the SEER Database

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 2639-2639
Author(s):  
Jayadev Manikkam Umakanthan ◽  
Dipesh Uprety ◽  
Vineela Kasireddy
Keyword(s):  
Multiple Myeloma ◽  
Survival Rate ◽  
Survival Rates ◽  
Relative Survival ◽  
Population Based ◽  
P Value ◽  
Relative Standard Error ◽  
Population Based Study ◽  
Male And Female ◽  
Relative Standard

Abstract Background: Bortezomib is an antineoplastic agent that acts through protease inhibition. Since, its approval in 2003 by U.S. Food and Drug administration, it has been used religiously for multiple myeloma. There is no current population based study that assesses the survival benefit in multiple myeloma from bortezomib. We conducted a population based study to evaluate the relative survival rates in multiple myeloma patients in pre and post-Bortezomib era in the United States. Methods: We analyzed the Surveillance, Epidemiology, and End Results (SEER) 18 registry database to compare five-year relative survival rates (RS) among multiple myeloma patients. The study arms were categorized by gender (male and female), race (Caucasians and African-Americans) and age (20-59, ≥60 years). The RS were compared between pre-bortezomib era (1991-2002) and post-bortezomib era (2004-2011). The survival rate accompanied standard errors and the statistical significance was defined as p value <0.05. Results: The database comprised of 57,328 patients. The RS have improved significantly during post-bortezomib era in all cohorts under consideration. There was no significant difference in survival rate between male and female and between the African American and Caucasian. However, the relative survival was much better with the young adult (20-59 years) as compared to adult ≥60 years. The table detailing the relative survival is given below. Conclusion: The Primary treatment protocols for Multiple Myeloma have changed dramatically since the approval of Bortezomib in 2003. Other novel agents introduced in the last decade include thalidomide, Lenalidomide and liposomal doxorubicin that are used in conjunction with Bortezomib. Survival trends continue to improve and we believe this modest improvement in survival rate is mainly due to the introduction of Bortezomib and other novel agents. The next challenge is to find new drugs which would prevent relapses and further prolong survival. Abstract 2639. Table.Study armSubclass of cohortsPre-bortezomib era (1991-2002)Post- bortezomib era (2004-2011)Z scoreP ValueNRS (%)Relative Standard Error (SE) (%)NRS (%)Relative Standard Error (SE) (%) GenderMale13,06634.60.517,76546.10.615.904<0.0001Female11,58032.10.514,91743.70.614.765<0.0001 RaceCaucasian18,83632.90.423,98145.00.519.259<0.0001African American4,27434.70.86,39145.10.98.488<0.0001 Age group20-596,35848.10.69,43960.20.712.920<0.0001>=6018,28827.80.423,24338.40.516.606<0.0001 Total: male and female: 1991-2002; 24,646, RS 33.4%; SE 0.3%; 2004-2011; 32,682, RS 45.0%, SE 0.4%; Z score 21.766, P value <0.0001. Disclosures No relevant conflicts of interest to declare.

scholarly journals Ovarian cancer with pleural and lung metastasis in Dr. Soetomo Hospital, Surabaya, Indonesia, in 2014-2015

2018 ◽  
Vol 26 (1) ◽  
pp. 7
Author(s):  
Fitria Khusnul Khotimah ◽  
Anna Febriani ◽  
Pungky Mulawardhana
Keyword(s):  
Ovarian Cancer ◽  
Survival Rate ◽  
Cancer Patients ◽  
Median Survival ◽  
Lung Metastasis ◽  
Survival Rates ◽  
Secondary Data ◽  
Pleural Metastasis ◽  
Histopathological Type ◽  
Median Survival Rate

Objectives: To know the characteristics of ovarian cancer patients with pleural and lung metastasis, and survival rates of ovarian cancer patients with pleural and lung metastasis in Dr. Soetomo Hospital Surabaya in 2014-2015.Materials & Methods: This was a descriptive observational study using secondary data from medical records in dr. Soetomo Hospital, Surabaya, Indonesia, in 2014 and 2015Results: Number of new patients of ovarian cancer in dr. Soe-tomo, Hospital, Surabaya in 2014 was 170 patients (14%) and 122 patients (12%) in 2015. Ovarian cancer patients most often came at the stage IIIC (33.38%) with the most histopathological type was epithelial ovarian cancer. There were 5 patients with ovarian cancer with pleural metastasis and 7 patients with lung metastasis. Pleural metastasis was 80% diagnosed at the time of ovarian cancer’s diagnosis, whereas 57.15% of lung metastasis were diag-nosed >12 months after the ovarian cancer’s diagnosis. Pleural metastasis was established by pleural fluid cytology, while lung metastasis with radiological features and/or biopsies. The most common feature of lung metastasis was nodal (71.42%). Ascites was found in 80% of ovarian cancer with pleural metastasis, but only 42.86% in lung metastasis. In 2 patients receiving NAC chemotherapy and continued by interval debulking, both had negative residues. Median survival rate in ovarian cancer with pleural metastasis was 7 months, whereas in lung metastasis was 12 months.Conclusions: Number of new patients of ovarian cancer in 2014-2015 in dr. Soetomo Hospital was on rising and was the second largest number of visits after cervical cancer. In 2014-2015, there were 5 patients with ovarian cancer and pleural metastasis and 7 patients with ovarian cancer patients and lung metastasis. Median survival rate in ovarian cancer with pleural metastasis was 7 months, whereas in lung metastasis it was 12 months.

scholarly journals Oropharyngeal Cancer Survival: A Population-Based Study of Patients Diagnosed between 1978 and 2002

ISRN Oncology ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Dyego Leandro Bezerra de Souza ◽  
María Milagros Bernal ◽  
Javier Jerez Roig ◽  
Maria Paula Curado
Keyword(s):  
Oropharyngeal Cancer ◽  
Cancer Survival ◽  
Survival Rates ◽  
Age Groups ◽  
Relative Survival ◽  
Population Based ◽  
First Year ◽  
Population Based Study ◽  
Kaplan Meier ◽  
One Year

Objective. This paper aims at studying oropharyngeal cancer survival from the Population-Based Cancer Registry of Zaragoza, Spain, for the 1978–2002 period. Methods. The survival rates were calculated by the Kaplan-Meier method, and the automated calculation method of the Catalan Institute of Oncology was utilized to obtain the relative survival. Results. The oropharyngeal cancer survival rate was 61.3% in the first year and 33.9% in the fifth year. One-year relative survival was 62.2% (CI 95%: 57.4–67.4), and five-year relative survival was 36.6% (CI 95%: 31.8–42.1). Comparison of survival rates by sex revealed statistically significant differences (P value = 0.017) with better survival in women. There were no differences when comparing the three age groups and the three studied time periods 1978–1986, 1987–1994, and 1995–2002. Conclusions. The data suggests that there were no significant changes in oropharyngeal cancer survival in the province of Zaragoza throughout the years.

scholarly journals Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Chunjing Jin ◽  
Minfeng Yang ◽  
Xueqiao Han ◽  
Haidan Chu ◽  
Yan Zhang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Survival Time ◽  
Median Survival ◽  
Median Survival Time ◽  
Cytokeratin 19 ◽  
Tumor Biomarker ◽  
Diagnostic Efficiency ◽  
Poor Prognostic Factor ◽  
Kaplan Meier

AbstractGrowing evidence indicates that the tumor biomarker cytokeratin 19 fragment (CYFRA21-1) is significant for a variety of cancers. However, its role in epithelial ovarian cancer (EOC) has rarely been reported. In this study, a receiver operating characteristic (ROC) curve was utilized to estimate the diagnostic efficiency of CYFRA21-1. The correlation between the CYFRA21-1 level and prognosis was analyzed by Kaplan-Meier survival analysis and univariable and multivariable analyses. The relationship between serum CYFRA21-1 levels and different clinicopathological variables was also analyzed. At the same time, the standard serum marker cancer antigen 125 (CA125) was measured. The results demonstrated that CYFRA21-1 expression was significantly increased in EOC compared with expression in benign ovarian diseases and healthy controls, which was similar to CA125 (P < 0.001). CYFRA21-1 expression was positively correlated with CA125 (r = 0.201; P = 0.0032). CYFRA21-1 expression was significantly correlated with lymph node metastasis and ascites (P < 0.001). Furthermore, the median survival time of EOC patients with high CYFRA21-1 expression was 42 months, compared with 54 months in the low CYFRA21-1 expression patients by Kaplan-Meier analysis (P < 0.05), while the high and low CA125 expression groups had no difference in median survival time. Univariate and multivariate analyses indicated that CYFRA21-1 was a poor prognostic factor associated with overall survival (OS), while CA125 was not. Our study indicates that CYFRA21-1 acts as a good complementary diagnostic biomarker and may be superior to CA125 as a prognostic indicator in EOC.

Sign in / Sign up

Export Citation Format

Share Document